Cytotoxic antibodies directed against antibodies inhibiting factor VIII
The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the FcγRIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.
1. An anti-idiotypic monoclonal antibody directed against an antibody inhibiting human factor VIII (FVIII), said inhibiting antibody being directed against the C2 region of human FVIII, wherein the constant regions of said anti-idiotypic antibody's light chains and heavy chains are constant regions originating from a non-murine species, wherein each of said anti-idiotypic antibody's light chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 5 and wherein each of said anti-idiotypic antibody's heavy chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 6, and wherein the fucose level/galactose level ratio of the glycan structures of said anti-idiot is antibody, present on the glycosylation site of the Fc region, is less than or equal to 0.6.
2. An anti-idiotypic monoclonal antibody directed against an antibody inhibiting human factor VIII (FVIII), said inhibiting antibody being directed against the C2 region of human FVIII, wherein the variable region of each of said anti-idiotypic antibody's light chains is encoded by the murine nucleic acid sequence SEQ ID NO: 1, the variable region of each of said anti-idiotypic antibody's heavy chains is encoded by the murine nucleic acid sequence SEQ ID NO: 2, the constant regions of said anti-idiotypic antibody's light chains and heavy chains are constant regions originating from a non-murine species, wherein each of said anti-idiotypic antibody's light chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 5, wherein each of said anti-idiotypic antibody's heavy chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 6, wherein the peptide sequence of each of said anti-idiotypic antibody's light chains is the peptide sequence SEQ ID NO: 7 and wherein the peptide sequence of each of said anti-idiotypic antibody's heavy chains is the peptide sequence SEQ ID NO: 8, and wherein the fucose level/galactose level ratio of the glycan structures of said anti-idiotypic antibody, present on the glycosylation site of the Fc region, is less than or equal to 0.6.
3. The anti-idiotypic monoclonal antibody according to claim 1 or 2 , characterized in that it is produced by a rat hybridoma cell line.
4. The anti-idiotypic monoclonal antibody according to claim 3 , wherein the anti-idiotypic antibody is produced in the rat hybridoma YB2/0 (cell YB2/3HL.P2.G11.16Ag.20, deposited at the American Type Culture Collection under number ATCC CRL-1662).
5. The anti-idiotypic monoclonal antibody according to claim 3 , wherein the anti-idiotypic antibody is capable of being produced by the clone R565 deposited under registration number 1-3510 in the Collection Nationale de Cultures de Microorganismes.
6. The anti-idiotypic monoclonal antibody according to claim 3 , wherein the anti-idiotypic antibody is the antibody EMAB565 produced by the clone R565 deposited under registration number I-3510 in the Collection Nationale de Cultures de Microorganismes.
7. A stable cell line expressing an antibody according to claim 1 or 2 .
8. An anti-idiotypic monoclonal antibody directed against an antibody inhibiting human factor VIII (FVIII), said inhibiting antibody being directed against the C2 region of human FVIII, wherein each of said anti-idiotypic antibody's light chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 5, and each of said anti-idiotypic antibody's heavy chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 6.
9. An anti-idiotypic monoclonal antibody directed against an antibody inhibiting human factor VIII (FVIII), said inhibiting antibody being directed against the C2 region of human FVIII, wherein the peptide sequence of each of the light chains of said anti-idiotypic antibody is the peptide sequence SEQ ID NO: 7 and the peptide sequence of each of the heavy chains of said anti-idiotypic antibody is the peptide sequence SEQ ID NO: 8.
10. An anti-idiotypic monoclonal antibody directed against an antibody inhibiting human factor VIII (FVIII), said inhibiting antibody being directed against the C2 region of human FVIII, wherein the constant regions of said anti-idiotypic antibody's light chains and heavy chains are constant regions originating from a non-murine species, wherein each of said anti-idiotypic antibody's light chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 5, and wherein each of said anti-idiotypic antibody's heavy chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 6.
11. An anti-idiotypic monoclonal antibody directed against an antibody inhibiting human factor VIII (FVIII), said inhibiting antibody being directed against the C2 region of human FVIII, wherein the constant regions of said anti-idiotypic antibody's light chains and heavy chains are constant regions originating from a non-murine species, wherein each of said anti-idiotypic antibody's light chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 5, wherein each of said anti-idiotypic antibody's heavy chains is encoded by the murine-human chimeric nucleic acid sequence SEQ ID NO: 6, wherein the peptide sequence of each of said anti-idiotypic antibody's light chains is the peptide sequence SEQ ID NO: 7, and wherein the peptide sequence of each of said anti-idiotypic antibody's heavy chains is the peptide sequence SEQ ID NO: 8.